News

Lilly, Mounjaro and Trulicity

Mounjaro appears more heart protective than Trulicity in trial of Eli Lilly diabetes drugs
Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling medication for the disease, in reducing the risk of heart attack and stroke in a large,
Lilly’s diabetes drug Mounjaro matches heart benefit of older treatment
Eli Lilly’s blockbuster diabetes drug Mounjaro matched the ability of an older treatment to prevent major heart complications in a large trial.
Lilly's Mounjaro shows its cardio benefits in Trulicity head-to-head trial
A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label expansions to reduce the risk of cardiovascular issues. | Eli Lilly has presented phase 3 results showing its Mounjaro measures up to the company’s GLP-1 Trulicity in reducing cardiovascular risks in patients with Type 2 diabetes and heart disease.
Lilly’s Mounjaro as Effective on Heart Risks as Older Drug
Eli Lilly & Co.’s blockbuster diabetes drug Mounjaro was about as good at preventing heart attacks and strokes as its older medicine Trulicity in a head-to-head study of the two treatments.
Eli Lilly Obesity Drug Mounjaro Beats Legacy Trulicity On Cardio-Renal Health
Eli Lilly's Mounjaro matched Trulicity in heart outcomes and showed added benefits on A1C, weight, kidney function, and mortality in a major trial.
Lilly’s Mounjaro protects heart health in large diabetic study
The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, while showing greater weight loss and blood sugar control.
Lilly shares slide as Mounjaro fails to outperform Trulicity in heart health study
Shares of Eli Lilly and Company (NYSE:LLY) dropped Thursday morning after the company announced that its diabetes treatment Mounjaro did not demonstrate superiority over Trulicity, its older GLP-1 medication,
Devdiscourse3d

Mounjaro Overshadows Trulicity in Life-Saving Diabetes Battle

Eli Lilly's Mounjaro diabetes drug has demonstrated superior performance over Trulicity in reducing heart attack and stroke ...

Lilly stock falls as Mounjaro fails to show superiority over Trulicity

Eli Lilly and Company (NYSE:LLY) stock fell on Thursday morning after the pharmaceutical giant’s diabetes drug Mounjaro ...
Medical Dialogues2d

Tirzepatide Matches dulaglutide in Heart Protection, Offers Added Benefits in SURPASS-CVOT trial

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...
Devdiscourse3d

Mounjaro Triumphs Over Trulicity: A New Era in Diabetes Care

Eli Lilly's diabetes drug Mounjaro demonstrated superior efficacy to its predecessor Trulicity in reducing heart attack and ...
BioSpace3d

Lilly’s Mounjaro ‘Good Enough’ in Cardio Trial, Will Seek Expanded Approval

While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase ...
STAT3d

Pharmalittle: We’re reading about Prasad’s downfall at FDA, Moderna job cuts, and much more

Moderna announced layoffs affecting 10% of its workforce amid government and competitive challenges to its vaccine business ...

Eli Lilly (LLY) Reports Results From SURPASS-CVOT Study: Mounjaro's Impact Analyzed

Eli Lilly (LLY) recently announced promising findings from its SURPASS-CVOT trial, revealing Mounjaro's potential benefits over Trulicity in reducing cardiovascular events. Despite these positive ...